Thu 20 Aug 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| Randomized, two-way, two-period, single injectable dose, open-label, crossover, bioequivalence study to compare Enoxa pre-filled syringes (80 mg enoxaparin sodium) versus Clexane® pre-filled syringes (80 mg enoxaparin sodium), in healthy subjects under fasting condition. | MEDIS Laboratories | Ongoing | Enoxa / Enoxaparin | 3 | 21-2017 | Saudi Ajal |
| Randomized, four-way, four-period, single oral dose, open-label, crossover, bioequivalence study to compare Tacrolimus Immediate-release capsules (5 mg tacrolimus) versus Prograf® Immediate-release capsules (5 mg tacrolimus), in healthy subjects under fasting conditions. | MEDIS Laboratories | Ongoing | Tacrolimus/ Prograf | 1 | 19-2017 | Saudi Ajal |
| Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma | King Faisal Specialist Hospital and Research Centre | Ongoing | Sorafenib (Nexavar) | 3 | RTOG 1112 | KFSH & RC-R |
| "Randomized clinical trial of neoadjuvant chemotherapy with denosumab compared to chemotherapy alone in hormonal receptor-positive, HER2-negative premenopausal breast cancer patients" | King Abdullah Medical City | Ongoing | DENOSUMAB | 3 | 20-610 | King Abdullah Medical City (Makkah) |
| "randomised, multicentre, double-blind, placebo-controlled study of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)" | GSK | Completed | Ambrisentan 5 mg | 3 | AMB115811 | KFMC |
| RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of Ranibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity | Novartis | Ongoing | Ranibizumab | 3 | CRFB002H2301 V 01 | KFSH & RC-R |
| "PROSPECTIVE, RANDOMIZED, OPEN LABEL CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF DEXMEDETOMIDINE USE BEYOND 24 HOURS COMPARED WITH MIDAZOLAM IN CHILDREN ADMITTED TO PEDIATRIC INTENSIVE CARE UNIT (PICU) AT KASCH-MNGHA. (PROMISE)" | KAIMRC | Rejected | Dexmedetomidine (Hospira) | 3 | RC20/160/R | King Abdulaziz Medical City NG (Riyadh) |
| Prospective, Randomized, Open label Controlled trial to evaluate the safety and efficacy of Dexmedetomidine Compared with Midazolam in children admitted to Pediatric Intensive Care unit (PICU) at KAMC-NGHA | KAIMRC | Rejected | Dexmedetomidine (Precedex) | 3 | RC11/084/R | NGHA-R |
| Prospective, Randomized, open label Controlled trial to evaluate the safety and efficacy of Dexmedetomidine Compared with Midazolam in children admitted to Pediatric Critical Care unit (PICU) at KAMC-NGHA (PROMISE) | KAIMRC | Rejected | Dexmedetomidine | 3 | RC11/084 | NGHA-R |
| Prospective, Open-label, Uncontrolled, Phase III Study to Assess the Efficacy and Safety of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery in Subjects With Congenital Fibrinogen Deficiency | Octapharma | Ongoing | Octafibrin | 3 | Forma 02 | KKUH |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.